Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Eganelisib by Infinity Pharmaceuticals for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Eganelisib is under clinical development by Infinity Pharmaceuticals and currently in Phase I for Oral Cavity (Mouth) Cancer. According to...
Eganelisib by Infinity Pharmaceuticals for Human Papillomavirus (HPV) Associated Cancer: Likelihood of Approval
Eganelisib is under clinical development by Infinity Pharmaceuticals and currently in Phase I for Human Papillomavirus (HPV) Associated Cancer. According...
Eganelisib by Infinity Pharmaceuticals for Nasopharyngeal Cancer: Likelihood of Approval
Eganelisib is under clinical development by Infinity Pharmaceuticals and currently in Phase I for Nasopharyngeal Cancer. According to GlobalData, Phase...
Eganelisib by Infinity Pharmaceuticals for Laryngeal Cancer: Likelihood of Approval
Eganelisib is under clinical development by Infinity Pharmaceuticals and currently in Phase I for Laryngeal Cancer. According to GlobalData, Phase...
Eganelisib by Infinity Pharmaceuticals for Hypopharyngeal Cancer: Likelihood of Approval
Eganelisib is under clinical development by Infinity Pharmaceuticals and currently in Phase I for Hypopharyngeal Cancer. According to GlobalData, Phase...
Eganelisib by Infinity Pharmaceuticals for Solid Tumor: Likelihood of Approval
Eganelisib is under clinical development by Infinity Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase...